Metabolic / GLP-1
Semaglutide
A long-acting GLP-1 receptor agonist researched for its role in glucose-dependent insulin secretion and reduced gastric emptying.
Quick facts
Molecular weight
4,114 Da
Half-life
168 h
Frequency
weekly
Admins / wk
1
Routes
SubQ
Typical dose
250 mcg–2.40 mg
Mechanism & positioning
A long-acting GLP-1 receptor agonist researched for its role in glucose-dependent insulin secretion and reduced gastric emptying.
Researched for: GLP-1 receptor agonism, glycaemic control, body-weight reduction.
Reconstitution defaults
Default vial
3 mg
BAC water
2 mL
Concentration
1500 mcg/mL
Doses per vial
~12
Other stocked vial sizes: 5, 10, 15 mg.
Calculate with this peptide
Dosage Calculator
Pre-filled for 250 mcg from a 3 mg vial in 2 mL BAC water.
Reconstitution Calculator
Auto-fills 3 mg + 2 mL BAC water + 250 mcg target dose.
Half-Life Calculator
Simulates steady-state at 250 mcg weekly.
Titration Schedule Builder
Stepwise escalation from 250 mcg to 2.40 mg.
Pen & Cartridge Calculator
Loads the Semaglutide 15 mg pen preset (15 mg / 3 mL).
Documented pairwise interactions
- avoid
Semaglutide + Tirzepatide
Both are long-acting incretin-class agents; stacking compounds gastric and metabolic effects.
- avoid
Semaglutide + Retatrutide
Overlapping GLP-1 receptor agonism; combined effects unpredictable in current literature.
References
- Wilding JPH et al., NEJM, 2021.
- Knudsen LB et al., Diabetes Obes Metab, 2010.
Related peptides in the Metabolic / GLP-1 class
Tirzepatide
A dual GIP and GLP-1 receptor agonist investigated for superior weight and glycaemic outcomes versus selective GLP-1 agonists.
Retatrutide
A triple agonist of GIP, GLP-1, and glucagon receptors currently in late-phase research for obesity and metabolic indications.
AOD-9604
A fragment of the C-terminus of human GH researched for stimulating lipolysis without affecting blood glucose or IGF-1.
SLU-PP-332
A small-molecule pan-ERR agonist investigated in preclinical models for inducing exercise-mimetic mitochondrial gene expression in muscle and adipose tissue.
5-Amino-1MQ
A small-molecule selective NNMT inhibitor investigated in preclinical models for reducing methyl-group sequestration in adipose tissue and restoring NAD+/SAM balance.
Adipotide
A peptidomimetic that homes to prohibitin receptors on white-adipocyte vasculature and triggers localised apoptosis; investigated only in preclinical primate models.